AACR Annual Meeting 2024: What to Know Before You Go
A few important details to help attendees get the most out of their experience at the AACR Annual Meeting...
A few important details to help attendees get the most out of their experience at the AACR Annual Meeting...
Three patients share their experiences about having Lynch syndrome.
In the opening keynote session of the AACR Special Conference on Pancreatic Cancer, which took place September 27-30 in...
Guest Post by Kelvin Lee, MD Roswell Park Cancer Institute
For the first time since 2019, the American Association for Cancer Research (AACR) Annual Meeting is set to return...
Studies featured at this year’s San Antonio Breast Cancer Symposium (SABCS) suggest that—in some situations—adjuvant radiotherapy may not be...
A team of mathematicians are designing an app that could help predict the likelihood of prostate cancer relapse.
The AACR Annual Meeting 2023, held April 14-19, commemorated several milestones, including the 25th anniversary of the approval of...
Unlike cancer incidence rates overall, which are decreasing in the United States, the incidence rate of liver cancer has been increasing...
Glioblastoma is an aggressive form of brain cancer. Less than 5 percent of patients diagnosed with this cancer type...
The American Association for Cancer Research (AACR) released its annual Cancer Progress Report today. The report serves as an important record of the...
For most solid tumors, traditional biopsies are the gold standard for diagnosing cancer and assessing molecular characteristics that may...
Clinical trials are an essential part of cancer research. They ensure that scientific discoveries are translated into advances in...
Cancers of the blood can initiate in a variety of cells, including in white blood cells (giving rise to lymphoma and leukemia) or in plasma cells...
Earlier this month, over 21,000 researchers, clinicians, patients, and other stakeholders gathered at the AACR Annual Meeting 2023 to...
This spring, in the inaugural year of the American Association for Cancer Research (AACR) Global-Scholar-In-Training Awards (GSITA) program, 15...
In the span of a decade, the idea that tumor-derived molecules circulating in the bloodstream and other body fluids...
Guest Post by Jonas de Souza, MD The University of Chicago Medicine
The AACR journal editors' picks for July 2024 include a review of the risks from CAR T-cell therapy, advances...
As the temperatures start to drop and the leaves begin to change color, enjoy the latest selection of studies...
Another month brings another round of Editors’ Picks! As we picked our May flowers, the editors picked their favorite...
With a five-year survival rate of only 12.5%, any progress toward new therapeutic approaches for pancreatic cancer is welcomed...
Guest Post by Matthew J. Sikora, PhD University of Pittsburgh Cancer Institute
“These are extraordinary times,” began Hugh Auchincloss, MD, as he opened up the recent NIH-AACR Cancer, Autoimmunity, and Immunology...
Guest Post by Dario C. Altieri, MD The Wistar Institute
As we enter the winter holiday season, it’s time for the latest edition of Editors’ Picks, our monthly staple...
“Are you ready to have a great meeting?” Robert Vonderheide, MD, DPhil, asked the nearly 11,000 attendees gathered in...
Researchers are exploring new options for kidney cancer treatments.
For June, the editors of the AACR’s 10 journals chose to spotlight a characterization of an investigational KRAS inhibitor,...
On Friday, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic olaparib (Lynparza) for treating certain...